Well Lead Medical Co (SHSE:603309) EBIT: ¥126 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603309 Well Lead Medical Co Ltd SHSE:603309
84 GF Score
Price ¥11.59
GF Value ¥14.48
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Well Lead Medical Co EBIT?

Well Lead Medical Co SHSE:603309 +0.17% 84 EBIT is ¥126 Mil as of Jun. 2026. GuruFocus rates SHSE:603309 with a GF Score™ of 84/100 and a GF Value™ of ¥14.48 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Well Lead Medical Co's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2026 was ¥60 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2026 was ¥126 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Well Lead Medical Co's annualized ROC % for the quarter that ended in Jun. 2026 was 10.48%. Well Lead Medical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 26.43%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Well Lead Medical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 3.55%.

Well Lead Medical Co  (SHSE:603309) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Well Lead Medical Co's annualized ROC % for the quarter that ended in Jun. 2026 is calculated as:

ROC % (Q: Jun. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2026 ) + Invested Capital (Q: Jun. 2026 ))/ count )
=265.388 * ( 1 - 16.11% )/( (2135.336 + 2114.636)/ 2 )
=222.6339932/2124.986
=10.48 %

where

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2751.583 - 222.134 - ( 460.038 - max(0, 474.724 - 868.837+460.038))
=2135.336

Invested Capital(Q: Jun. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2725.168 - 247.635 - ( 434.596 - max(0, 493.532 - 856.429+434.596))
=2114.636

Note: The Operating Income data used here is four times the quarterly (Jun. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Well Lead Medical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2026  Q: Jun. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=241.08/( ( (785.813 + max(139.431, 0)) + (777.205 + max(121.966, 0)) )/ 2 )
=241.08/( ( 925.244 + 899.171 )/ 2 )
=241.08/912.2075
=26.43 %

where Working Capital is:

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(178.008 + 186.839 + 28.885) - (222.134 + 0 + 32.167)
=139.431

Working Capital(Q: Jun. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(192.065 + 199.417 + 17.072) - (247.635 + 0 + 38.953)
=121.966

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Well Lead Medical Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2026 )
=125.959/3550.758
=3.55 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Well Lead Medical Co EBIT Related Terms

Well Lead Medical Co EBIT Historical Data

* Premium members only.

The historical data trend for Well Lead Medical Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Well Lead Medical Co EBIT Chart

Well Lead Medical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 148.71 213.52 246.43 275.36 148.47

Well Lead Medical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 85.32 86.47 -97.37 76.59 60.27

SHSE:603309 vs ISRG, BDX, MDLN: EBIT Comparison

For the Medical Instruments & Supplies subindustry, Well Lead Medical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Well Lead Medical Co EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Well Lead Medical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Well Lead Medical Co's EV-to-EBIT falls into.


SHSE:603309
84GF Score
Well Lead Medical Co Ltd SHSE:603309
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Well Lead Medical Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥126 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ¥126 Mil mean?
Well Lead Medical Co (SHSE:603309) has a EBIT of ¥126 Mil as of Jun. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Well Lead Medical Co.
Is Well Lead Medical Co's EBIT too high?
Well Lead Medical Co's current EBIT is ¥126 Mil. Overall, Well Lead Medical Co has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Well Lead Medical Co's EBIT compare to ISRG and BDX?
Well Lead Medical Co's EBIT of ¥126 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Well Lead Medical Co. Well Lead Medical Co's current EBIT is ¥126 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Well Lead Medical Co stock overvalued right now?
Based on GuruFocus' analysis, Well Lead Medical Co (SHSE:603309) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥14.48, compared to a current price of ¥11.59 — trading 20% below its estimated fair value. The current EBIT is ¥126 Mil. Well Lead Medical Co's overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Well Lead Medical Co (SHSE:603309), the current EBIT is ¥126 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Well Lead Medical Co (SHSE:603309) Overvalued in 2026?

Based on GuruFocus' analysis, Well Lead Medical Co stock appears to be undervalued. The current stock price of ¥11.59 is trading 20% below its estimated GF Value™ of ¥14.48. GuruFocus considers Well Lead Medical Co to be Modestly Undervalued.

Key valuation signals for SHSE:603309:

  • EBIT: ¥126 Mil
  • GF Value™: ¥14.48 vs. price of ¥11.59 (20% below fair value)
  • GF Score™: 84/100 with 4 warning signs

No single metric tells the full story. See the SHSE:603309 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Well Lead Medical Co Business Description

Address No. 45-47, South of Guomao Avenue, No. 4, Area C, Jinhu Industrial City, Hualong Town, Panyu District, Guangdong Province, Guangzhou City, CHN, 511434
Well Lead Medical Co Ltd is engaged in research, production, and sales of medical catheters in anaesthesia, urology, respiratory and hemodialysis region. Its products include Endotracheal Tube, Standar Endotracheal Tube, and Suction Endotracheal Tube. The company products are used in surgery, treatment, first aid, and nursing. The company exports its products to North America, Europe, and Japan.
84GF Score

Get the complete analysis for SHSE:603309

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥11.59
Price
¥14.48
GF Value